Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.Objective To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.Design Randomized double-blind controlled cross-over trial.Setting Community and hospital-based.Participants Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.Interventions Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.Measurements (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.Results Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).Conclusion Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2006
In the citing paper
“ACCORD, like the UKPDS, demonstrated that improved glucose control reduced microvascular complications126”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [126]
Citations
Cites
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans
Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999) · Science · doi:10.1126/science.283.5399.212 · Cited by 997
Reliability and validity of the combined heart rate and movement sensor Actiheart
Brage, S., Brage, N., Franks, P. W., Ekelund, U., & Wareham, N. J. (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602118 · Cited by 667
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P. J. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2984 · Cited by 534
Self-citationBrage, S., Brage, N., Franks, P. W., Ekelund, U., Wong, M.-Y., Andersen, L. B., Froberg, K., & Wareham, N. J. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00703.2003 · Cited by 473
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Self-citation
Cited by
Items 201–300 of 365
G Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Halquist, M. S., Sakagami, M., & Karnes, H. T. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.06.047 · Cited by 20
Li, W., Kirchner, T., Ho, G., Bonilla, F., D'Aquino, K., Littrell, J., Zhang, R., Jian, W., Qiu, X., Zheng, S., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14173 · Cited by 20
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
Kueh, M. T. W., Chong, M. C., Miras, A. D., & le Roux, C. W. (2024) · The Journal of Physiology · doi:10.1113/jp287407 · Cited by 24
“%) along with long-term efficacy in weight loss (Wynne et al., 2006).”
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
Melvin, A., le Roux, C. W., & Docherty, N. G. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0599-9 · Cited by 24
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
“When administered to obese subjects, this peptide successfully reduced calorie intake and increased EE, resulting in negative energy balance and significant weight loss [221].”
BackgroundField, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 23
The role of gut hormones in obesity
Mok, J., Makaronidis, J., & Batterham, R. L. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.09.005 · Cited by 20
“Intravenous administration of supra-physiological levels of native gut hormones PYY, GLP-1, amylin and OXM leads to reduced appetite and decreased energy intake[18, 26, 60, 61].”
BackgroundProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 20
“In fact, peripheral infusion and chronic subcutaneous injection of OXM resulted in reduction of food intake, weight loss, and increase in activity-related energy expenditure in humans [61,63].”
BackgroundSelf-citationGolubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
“50 In a double-blind, randomized, crossover trial using infusions of GLP-1, glucagon, GLP-1 and glucagon co-infusion, and placebo in obese adults without diabetes, Tan et al. 16 demonstrated a significant increase in REE after glucagon and after GLP-1 and glucagon co-infusion, but not after GLP-1…”
BackgroundSelf-citationNeff, L. M., & Aronne, L. J. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0061-0 · Cited by 22
Brown adipose tissue clinical impact of a re-discovered thermogenic organ
Vijgen, G. H. E. J., & Lichtenbelt, W. V. M. (2013) · Frontiers in Bioscience-Elite · doi:10.2741/e663 · Cited by 18
An investigation of the neural mechanisms underlying the efficacy of the adjustable gastric band
Stefanidis, A., Forrest, N., Brown, W. A., Dixon, J. B., O’Brien, P. B., Kampe, J., & Oldfield, B. J. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.11.020 · Cited by 17
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 18
“Moreover, energy intake was lower on day 2 and day 29 compared to day 1, suggesting that weight loss could be maintained over time [70].”
BackgroundPopulation Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes
Ye, G., Ly, N. S., Li, J., & Arends, R. H. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01094-y · Cited by 16
“Oxyntomodulin, a naturally occurring peptide with GLP-1 and glucagon receptor co-agonist activity, has been shown to promote weight loss through effects on appetite and energy expenditure [5], and co-infusion of GLP-1 and glucagon has synergistic effects on reducing food intake and promoting weight loss in human subje…”
BackgroundCentral administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Sutariya, B., Patel, M. S., Patel, H., Pandey, D., Patel, D. N., Bahekar, R. H., & Jain, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.068 · Cited by 18
Peters, H. P. F., & Mela, D. J. (2008) · CRC Press eBooks · doi:10.1201/9781420047844.ch10 · Cited by 16
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 17
Self-citationGut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Will, S., Hornigold, D. C., Baker, D. J., Coghlan, M. P., Mesquita, M., Trevaskis, J. L., & Naylor, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.010 · Cited by 16
Thomas, L. H., Martel, E., Rist, W., Uphues, I., Hamprecht, D. W., Neubauer, H., & Augustin, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15551 · Cited by 16
“15 22 Glucagon is the key counter-regulatory hormone of insulin, and the development of GCGR agonists has been hampered by a glucose-centric perspective on glucagon's ability to cause hyperglycaemia at pharmacological levels.”
BackgroundRole of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare, K. J. (2010) · PubMed · Cited by 18
Approaches to the pharmacological treatment of obesity
Salem, V., & Bloom, S. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15
Self-citationMazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Bhattachar, S., Tham, L. S., Yan, L., Chua, L., Ng, S., Tang, Y., Ibriga, H., Ni, W., Gurbuz, S., Mather, K. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70040 · Cited by 15
A glucagon analogue decreases body weight in mice via signalling in the liver
Hinds, C. E., Owen, B. M., Hope, D. C. D., Pickford, P., Jones, B. J., Tan, T., MINNION, J. S., & Bloom, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01912-0 · Cited by 15
Self-citationMeasurement of Energy Expenditure
Westerterp, K. R. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_7 · Cited by 14
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Melander, S. A., Kayed, A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176215 · Cited by 11
The Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 13
“In a second placebo-controlled, crossover study, reductions in food intake with oxyntomodulin were accompanied by increased energy expenditure [48] .”
BackgroundRetatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
“It has shown to decrease weight significantly in both normal weight individuals and people living with overweight in trials without hampering glucose tolerance [26,27], and this encouraged consideration of glucagon receptor agonism for body weight reduction.”
BackgroundNeural circuits of eating behaviour: Opportunities for therapeutic development
Clifton, P. G. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117738629 · Cited by 14
“, 2001) and has the same effect in humans by both increasing energy expenditure and reducing energy intake (Wynne et al., 2006).”
BackgroundPalani, A., Nawrocki, A. R., Orvieto, F., Bianchi, E., Mandić, E., Pessi, A., Huang, C., Deng, Q., Toussaint, N., Walsh, E., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00217 · Cited by 12
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
“7 kg in human subjects [83], and a separate study demonstrated that OXM administration both suppressed appetite and increased energy expenditure in patients [83].”
Zhao, L., Wang, B., Wang, L., Xie, Z., Chen, Z., & Li-xia, S. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01132c · Cited by 10
Models and Strategies in the Development of Antiobesity Drugs
Agahi, A., & Murphy, K. G. (2013) · Veterinary Pathology · doi:10.1177/0300985813492801 · Cited by 11
“Peripheral ghrelin administration stimulates acute food intake in rats and humans, and chronic administration promotes weight gain in rats.(130,141,142) However, ghrelin antagonists have to date proven of limited efficacy in the clinical management of obesity.”
BackgroundTherapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 13
“Weight loss occurs as a result of reduced food intake, and possibly because of increased energy expenditure [64].”
BackgroundOxyntomodulin - past, present and future
Holst, J. J., & ROSENKILDE, M. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171393 · Cited by 12
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“Initial evidence for the success of this rationale came from the reduced energy intake and increased total energy expenditure in man caused by oxyntomodulin administration, a natural GLP-1 R/GCGR dual agonist derived from the prepro-glucagon gene [72].”
BackgroundIncreased food intake with oxyntomodulin analogues
Price, S. L., MINNION, J. S., & Bloom, S. R. (2015) · Peptides · doi:10.1016/j.peptides.2015.09.006 · Cited by 11
Self-citationNovel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 12
The role of the gastrointestinal tract in the control of energy balance
Boguszewski, C. L., & van der Lely, A. J. (2014) · Translational gastrointestinal cancer · doi:10.3978/j.issn.2224-4778.2014.07.01 · Cited by 13
Löf, M., Henriksson, H., & Forsum, E. (2013) · Journal of Nutritional Science · doi:10.1017/jns.2013.18 · Cited by 10
“Such a combination is used in the Actiheart monitor (CamNtech Ltd), which has been applied in studies to assess AEE in pregnant((8)) and obese((9,10)) subjects.”
MethodLiu, F., Wang, S., Guo, X., Ye, Z.-X., Zhang, H., & Li, Z. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.632 · Cited by 9
Wan, H., Xu, N., Wang, L., Liu, Y., Fatahi, S., Sohouli, M. H., & Guimarães, N. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01501-x · Cited by 8
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Can Bayliss and Starling gut hormones cure a worldwide pandemic?
Scott, R., Tan, T., & Bloom, S. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272955 · Cited by 10
Self-citationHypothalamo-gastrointestinal axis – role in food intake regulation
Wójcik-Gładysz, A., & Szlis, M. (2016) · Journal of Animal and Feed Sciences · doi:10.22358/jafs/65569/2016 · Cited by 8
“Intravenous administration of OXM reduces food intake and increases energy expenditure both in healthy and obese human (Wynne et al., 2006).”
BackgroundPhysiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
“The beneficial effects of the combined activation of GLP-1 and glucagon receptors are also supported by reports showing that oxyntomodulin which is produced by L-cells and is a weak coagonist of glucagon and GLP-1 receptors suppresses appetite, increases energy expenditure, and reduces weight loss (Cohen et al. 2003;…”
BackgroundFrom Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes
Guimarães, M., Pereira, S. S., & Monteiro, M. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_480 · Cited by 9
Valsamakis, G., Lois, K. B., Kumar, S., & Mastorakos, G. P. (2014) · Clinical Obesity · doi:10.1111/cob.12064 · Cited by 7
“Human studies have shown an additional effect of OXM on energy expenditure, beyond that of food intake restriction (70).”
BackgroundAdvancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
“When used in overweight and obese volunteers, oxyntomo-dulin was shown to reduce energy intake while at the same time increasing energy expenditure [94].”
BackgroundIsidro, M. L., & Cordido, F. (2010) · Pharmaceuticals · doi:10.3390/ph3010125 · Cited by 12
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
“Oxyntomodulin is co-released by L-cells alongside GLP-1 and may contribute to physiological glucose homeostasis and appetite control(Shankar et al., 2018) as it exerts agonistic activity on both GLP-1 and glucagon receptors (Wynne et al., 2006; Pocai, 2014).”
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Wharton, S., le Roux, C. W., Startseva, E., Kloer, I. M., Alhussein, A., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2607219 · Cited by 8
Factors Affecting the Circulating Levels of Oxyntomodulin in Health and After Acute Pancreatitis
Bharmal, S. H., Ko, J., Kimita, W., Cho, J., & Petrov, M. S. (2022) · Pancreas · doi:10.1097/mpa.0000000000002114 · Cited by 6
“Oxyntomodulin has been shown to cause weight loss in overweight and obese humans by lowering their food intake and increasing their energy expenditure.(5,6) Further, a 2021 randomized controlled trial using functional magnetic resonance imaging (MRI) showed that high fasting circulating levels of oxyntomodulin were si…”
BackgroundPrice, S. L., MINNION, J. S., & Bloom, S. R. (2015) · Current Therapeutic Research · doi:10.1016/j.curtheres.2015.10.003 · Cited by 8
“Administration of OXM to rodents and humans reduces food intake and increases energy expenditure, generating significant weight loss and highlighting OXM as a potential pharmacologic treatment for obesity.(3,4) Due to the short in vivo half-life of native OXM,(5) it is necessary to produce long-lasting analogues for c…”
BackgroundSelf-citationPark, S.-H., Lee, J.-R., Jang, S.-P., Park, S.-H., Lee, H.-J., Hong, J.-W., & Suh, H. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.01.002 · Cited by 6
[Mechanisms of regulation of the food intake: recent advances].
Loviselli, A., Secci, G., Lai, A., & Velluzzi, F. (2007) · PubMed · Cited by 5
Measurement of Energy Expenditure
Westerterp, K. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_4 · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
Self-citationNew Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Gut hormones regulating appetite and metabolism
McGowan, B. M., & Bloom, S. R. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2007.10.004 · Cited by 5
Self-citationTreatment of obesity: bariatric surgery
Neff, K., Ferrannini, E., & le Roux, C. W. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch34 · Cited by 5
Doctor-patient interactions during medical consultations about obesity.
Webb, H. (2009) · Nottingham ePrints (University of Nottingham) · Cited by 11
Dutta, D., Kamrul-Hasan, A. B. M., Joshi, A. S., Dhall, A., Nagendra, L., & Sharma, M. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_366_24 · Cited by 4
Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review
Tzeravini, E., Simati, S., Anastasiou, I. A., Dalamaga, Μ., & Kokkinos, A. D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00687-7 · Cited by 8
“Beyond glycemia, OXM reduces food intake and increases energy expenditure, contributing to weight loss that may surpass GLP-1 receptor agonists [57, 59, 60].”
Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats
Akalestou, E., Christakis, I. A., Solomou, A., MINNION, J. S., Rutter, G. A., & Bloom, S. R. (2016) · Pancreas · doi:10.1097/mpa.0000000000000585 · Cited by 5
Self-citationExercise and Training Effects on Appetite-Regulating Hormones in Individuals with Obesity
Zouhal, H., Saeidi, A., Kolahdouzi, S., Ahmadizad, S., Hackney, A. C., & Abderrahman, A. B. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-33376-8_30 · Cited by 5
Huang, P., Meng, L., Tan, J., Gu, X., Huang, M., Huang, F., Ma, R., & Wang, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119136 · Cited by 4
Thermo-Responsive self-assembly of a dual glucagon-like peptide and glucagon receptor agonist
Kinna, S., Ouberai, M. M., Sonzini, S., dos Santos, A. L. G., & Welland, M. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120719 · Cited by 4
Brain Related Gut Peptides – A Review
Manoharan, N., Jayamurali, D., Parasuraman, R., & Govindarajulu, S. N. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220920150127 · Cited by 4
Gut hormones and Type 2 diabetes mellitus
Falinska, A. M., Tan, T., & Bloom, S. R. (2014) · Diabetes Management · doi:10.2217/dmt.14.47 · Cited by 4
Self-citationSizing Up Pharmacotherapy for Obesity
Valentino, M. A., Terzic, A., & Waldman, S. A. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00191.x · Cited by 6
Satiety, weight management and foods : literature review
Salmenkallio‐Marttila, M., & Gunnarsdóttir, I. (2009) · Cited by 10
Kanbay, M., Çöpür, S., Güldan, M., Özbek, L., Mallamaci, F., & Zoccali, C. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14330 · Cited by 4
“15 Nevertheless, the short half-life of oxyntomodulin requiring three times daily preprandial subcutaneous administration is the major limitation of such a therapeutic alternative.”
Griffith, L. D., Haddad, E. H., & Tonstad, S. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.08.001 · Cited by 6
Cantini, G., Trabucco, M., Dicembrini, I., Mannucci, E., & Luconi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00016-x · Cited by 3
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-18159-2_184-1 · Cited by 3
Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity
Valentino, M. A., Colón‐González, F., Lin, J. E., & Waldman, S. A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.33 · Cited by 5
Mechanisms of Action of Bariatric Surgical Procedures
Neff, K., & le Roux, C. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-04343-2_54 · Cited by 3
Stensel, D. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-10343-8.00002-0 · Cited by 4
Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Flatt, P. R., & Gault, V. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00035-9 · Cited by 3
Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?
Кушнарьова, Н. М., Zinych, О. В., Korpachev, V. V., Ковальчук, А., Prybyla, О. В., & Shyshkan-Shyshova, К. О. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246799 · Cited by 3
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
Salagre, D., Mosqueda, C. V. A., Aouichat, S., & Agil, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091247 · Cited by 2
Cho, Y. H., & Lee, S. Y. (2013) · The Korean Journal of Obesity · doi:10.7570/kjo.2013.22.4.197 · Cited by 2
“디펩티딜 펩티드분해효소(dipeptidyl peptide IV, DPP-IV) 에 의해 GLP-1(9-37) 또는 GLP-1(9-36) 아미드로 비활성 화되며, 반감기는 약 2분에 불과하다.”
Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
Anderson, S. L. (2025) · Drugs in Context · doi:10.7573/dic.2025-4-8 · Cited by 4
Metabolic Effects of Bariatric Surgery: A Focus on Inflammation and Diabetic Kidney Disease
Neff, K., & le Roux, C. W. (2013) · Current Obesity Reports · doi:10.1007/s13679-013-0050-2 · Cited by 3
“Oxyntomodulin, which mediates some of its action through the GLP-1 receptor, increases energy expenditure while reducing energy intake in overweight and obese humans [64].”
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00034-2 · Cited by 2
Mechanisms of Action of Different Bariatric Surgical Procedures
Neff, K., & le Roux, C. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_103 · Cited by 2
Pharmacotherapy of Childhood Obesity and Pre-diabetes
Freemark, M. (2010) · Springer eBooks · doi:10.1007/978-1-60327-874-4_23 · Cited by 2
Physiology of Weight Regulation
Chaptini, L. A., Deitch, C., & Peikin, S. R. (2010) · Wiley eBooks · doi:10.1002/9781444328417.ch2 · Cited by 2
An investigation into age-associated undernutrition
Moss, C. (2012) · Spiral (Imperial College London) · doi:10.25560/11181 · Cited by 3
“Pre-prandial subcutaneous injections of OXM to obese subjects for 4 weeks produced an average of 2.3kg weight loss compared to 0.5kg with placebo (Wynne et al., 2006).”
BackgroundPhysiology of Weight Regulation
Chaptini, L. A., & Peikin, S. R. (2016) · Wiley eBooks · doi:10.1002/9781119127437.ch102 · Cited by 3
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, S R
- Venue
- International Journal of Obesity
- Published
- 2006-04-18
- Volume
- 30
- Issue
- 12
- Pages
- 1729-1736
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2135978651
- Cited by
- 363
- References
- 32
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 15 · 2021: 22 · 2020: 18 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 32 · 2012: 24
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, energy expenditure, energy intake, obesity, overweight, obesity treatment, physical activity, weight loss, negative energy balance, GLP-1 receptor agonists
- MeSH terms
- Adult, Blood Pressure, Energy Intake, Double-Blind Method, Energy Metabolism, Female, Heart Rate, Humans, Injections, Subcutaneous, Insulin, Male, Middle Aged, Obesity, Self Administration, Body Mass Index, Cross-Over Studies, Anti-Obesity Agents, Overweight, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.